• Trelagliptin succinate (SKU A3889): Reliable Solutions for D

  2026-08-05

  This scenario-driven guide demonstrates how Trelagliptin succinate (SKU A3889) addresses laboratory challenges in diabetes mellitus research, osteoblastic differentiation, and cytotoxicity workflows. Drawing on validated data and peer-reviewed studies, it provides practical, evidence-based recommendations for assay optimization and vendor selection. Researchers can rely on APExBIO’s Trelagliptin succinate for reproducibility and data integrity across diverse experimental models.

• Axitinib (AG 013736): Precision Tools for Angiogenesis Assay

  2026-08-04

  Axitinib (AG 013736) delivers unmatched selectivity and potency for dissecting VEGF signaling in cancer biology research. Explore protocol-driven workflows, troubleshooting insights, and practical guidance for maximizing reproducibility in angiogenesis and tumor growth inhibition studies.

• Viperin Inhibits Coronavirus Replication by Disrupting nsp8–

  2026-08-04

  This study uncovers a conserved mechanism by which the interferon-induced enzyme viperin restricts coronavirus replication. By targeting non-structural protein 8 (nsp8) and disrupting the assembly of the replication-transcription complex, viperin impairs viral RNA synthesis, revealing new antiviral intervention points and clarifying the dual role of viperin in both ddhCTP production and direct RTC inhibition.

• Phos binding reagent (Phosbind) acrylamide: Reliable Phospho

  2026-08-03

  This article addresses key workflow challenges in phosphorylation analysis, demonstrating how Phos binding reagent (Phosbind) acrylamide (SKU F4002) streamlines SDS-PAGE detection of phosphorylated proteins without the need for antibodies. Scenario-driven guidance, protocol parameters, and literature-backed advice highlight its reliability and practical value for biomedical researchers.

• Viral Targeting of RIPK3 Regulates Necroptosis and Inflammat

  2026-08-03

  The referenced study identifies a viral mechanism whereby orthopoxviruses, such as cowpox virus, induce proteasomal degradation of the necroptosis adaptor RIPK3 to suppress host inflammatory responses. This finding clarifies how viral inhibitors modulate cell death pathways, with significant implications for understanding virus-induced pathogenesis and immune evasion.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Optimizing Dual Reporter mR

  2026-08-02

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) combines Cy5 fluorescence and EGFP expression to streamline mRNA delivery, tracking, and translation efficiency in advanced gene regulation workflows. Its immune-evasive chemistry and dual-reporter design empower direct, quantitative cellular analysis that surpasses conventional single-label systems.

• Ciprofloxacin Hydrochloride: Mechanism, Evidence, and Resear

  2026-08-01

  Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic with proven efficacy as a bacterial DNA replication inhibitor and immunomodulatory agent. Its benchmarked activity underpins FDA-approved anthrax treatment and advanced research on apoptosis modulation. This article details its mechanism, evidence, and research integration.

• Trelagliptin Succinate Improves Insulin Resistance via PI3K/

  2026-07-31

  This study demonstrates that trelagliptin succinate (SYR-472 succinate), a long-acting DPP-4 inhibitor, enhances insulin sensitivity in adipocytes by upregulating the PI3K/Akt/GLUT4 signaling pathway and reducing adipokine-mediated insulin resistance. These mechanistic insights broaden the understanding of DPP-4 inhibitors in type 2 diabetes research beyond glucose lowering alone.

• Anagliptin (SK-0403): Applied DPP-4 Inhibition in Vascular R

  2026-07-31

  Anagliptin (SK-0403) offers researchers a uniquely selective DPP-4 inhibitor for dissecting glycemic and vascular mechanisms. Its proven engagement with Kv channels and the SERCA pump provides new avenues for metabolic-cardiovascular interface studies, as well as troubleshooting guidance for assay optimization.

• ML385: Applied NRF2 Inhibitor Protocols for Cancer & Ferropt

  2026-07-30

  ML385, a selective NRF2 inhibitor from APExBIO, enables precise dissection of antioxidant signaling and therapeutic resistance in cancer and neurodegeneration models. Recent breakthroughs reveal how ML385 advances both oncology and ferroptosis research, with protocol-ready parameters and troubleshooting tips that streamline NRF2 pathway interrogation.

• Isoliensinine Modulates TRPV1–AMPK to Attenuate MAFLD Fibros

  2026-07-30

  This study reveals that isoliensinine from Plumula Nelumbinis significantly attenuates hepatic fibrosis in metabolic associated fatty liver disease (MAFLD) by restoring lipid droplet metabolism in hepatic stellate cells through TRPV1–AMPK/ACC pathway activation. The findings highlight a novel mechanism for energy metabolism regulation in liver fibrosis, with practical implications for metabolic disease research and anti-fibrotic strategy development.

• Dihydroethidium (DHE) for Live-Cell Superoxide Detection Wor

  2026-07-29

  Dihydroethidium (DHE) delivers robust, quantitative superoxide detection in live cells, powering advanced oxidative stress assays across disease models. This guide translates frontline research into actionable protocols, troubleshooting, and workflow enhancements for mitochondrial redox interrogation, with practical focus on apoptosis and metabolic disease.

• Refining In Vitro Drug Response Assessment in Cancer Researc

  2026-07-29

  Schwartz’s 2022 dissertation introduces a critical dual-metric approach to evaluating anticancer drug responses in vitro, distinguishing between proliferative arrest and cell death. This methodological advance clarifies drug mechanisms and supports more rigorous preclinical screening, with direct implications for cancer biology and workflow optimization.

• AG-221 (Enasidenib) for IDH2-Mutant AML: Reliable Lab Soluti

  2026-07-28

  This article explores reproducible, data-driven strategies for acute myeloid leukemia research using AG-221 (Enasidenib), SKU B7804. Scenario-based Q&A blocks address practical challenges in cell viability, differentiation assays, and product selection, highlighting AG-221's validated performance and workflow compatibility. The guide empowers biomedical researchers with actionable insights grounded in current literature and product specifics.

• Aprotinin (BPTI): Mechanistic Insights and Emerging Roles in

  2026-07-28

  Discover how aprotinin, a potent bovine pancreatic trypsin inhibitor, uniquely modulates fibrinolysis and membrane integrity in cardiovascular research. This article draws on new membrane biophysics findings to illuminate advanced applications and protocol strategies.

8024 records 3/535 page Previous Next 12345 下5页 Last page